Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: A phase II, multicentre, randomised, dose-finding, double-blind and placebo-controlled study.
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs PR 15 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- 15 Nov 2017 Status changed from not yet recruiting to recruiting.
- 14 Jul 2016 New trial record